IP Library Granted Patent US 11,001,611
Granted Patent B2
US 11,001,611 · App. 16/134,179 · Granted May 11, 2021

Site-specific bio-conjugation methods and compositions useful for nanopore systems

Inventors: Dmitriy Gremyachinskiy (San Francisco, CA); Christos Tzitzilonis (Redwood City, CA)
Assignee: Roche Sequencing Solutions, Inc.
C07K14/315A61K47/64A61K47/6415C07K1/1072C07K1/1077C07K19/00C12N9/1205C12N9/1241C12N9/52C12N15/62C12Q1/68C07K2319/03C07K2319/20C12Y207/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,001,611
App. No.
16/134,179
Granted
May 11, 2021
Kind
B2
Abstract

The present disclosure relates to relates methods and associated compositions that provide fast, efficient site-selective conjugation of a protein, such as the pore-forming protein α-hemolysin, to a biomolecule, such as a DNA polymerase, and the use of such site-selective protein-biomolecule conjugates in nanopore devices and methods.

Claims (15)

1. A composition comprising a conjugate of a protein and a biomolecule of formula (Vh) or (Vi):

wherein,

n=1 to 50, and q, r, and s each independently=0, 1, 2, or 3;

L B is a linker;

B is a SpyTaq peptide;

and wherein the protein contains a thiol group

Z is a SpyCatcher protein.

2. The composition of claim 1 , wherein the SpyTag peptide and SpyCatcher protein each comprise a fragment of an amino acid sequence of the CnaB2 domain from the Streptococcus pyogenes fibronectin binding protein FbaB.

3. The composition of claim 1 , wherein the protein is a pore-forming protein, optionally selected from the group consisting of α-hemolysin, β-hemolysin, γ-hemolysin, aerolysin, cytolysin, leukocidin, melittin, MspA porin and porin A.

4. The composition of claim 1 , wherein the protein is a pore-forming protein embedded in a membrane.

5. The composition of claim 1 , wherein the biomolecule is an enzyme capable of catalyzing the synthesis of a polymer, selected from the group consisting of a DNA polymerase, RNA polymerase, reverse transcriptase, and DNA ligase.

6. The composition of claim 1 , wherein the conjugate of formula (Vh) comprises a compound of formula (Vk):

7. The composition of claim 6 , wherein the protein is α-hemolysin and the biomolecule is DNA polymerase.

8. The composition of claim 1 , wherein the conjugate of formula (Vi) comprises a compound of formula (Vm):

9. The composition of claim 8 , wherein the protein is α-hemolysin and the biomolecule is DNA polymerase.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2020
From: GREMYACHINSKIY, DMITRIY; TZITZILONIS, CHRISTOS
To: ROCHE MOLECULAR SYSTEMS, INC.
Reel/Frame 052272/0170 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2020
From: ROCHE MOLECULAR SYSTEMS, INC.
To: GENIA TECHNOLOGIES, INC.
Reel/Frame 052272/0291 →
MERGER Recorded Mar 31, 2020
From: GENIA TECHNOLOGIES, INC.
To: ROCHE SEQUENCING SOLUTIONS, INC.
Reel/Frame 052272/0341 →
Continuity (3)
Continuation PCTEP2017057002 · Mar 23, 2017
Provisional Application 62313086 · Mar 24, 2016
Related Publication 20190002509A1 · Jan 3, 2019
Cited By (1)
US 12,251,438